Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
Canada
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. 5-(2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1h-quinolin-2-one
2. Arcapta Neohaler
3. Indacaterol
4. Onbrez
5. Qab-149
1. 753498-25-8
2. Arcapta Neohaler
3. Indacaterol (maleate)
4. Indacterol Maleate
5. Indacaterol Maleate [usan]
6. Qab149-afa
7. Qab-149-afa
8. Indacaterol (as Maleate)
9. 2jec1itx7r
10. Chebi:68573
11. 753498-25-8 (malate)
12. Qabi49
13. (r)-5-(2-((5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one Maleate
14. Qab-149 Maleate
15. Unii-2jec1itx7r
16. Qab 149afa
17. Oslif Breezhaler
18. Onbrez Breezhaler
19. Hirobriz Breezhaler
20. (r)-5-[2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one Maleate
21. Arcapta Neohaler (tn)
22. Onbrez Inhalation Capsules
23. Indacaterol Maleic Acid Salt
24. Schembl523627
25. Chembl1789842
26. Indacaterol Maleate [mi]
27. Indacaterol Maleate (jan/usan)
28. Indacaterol Maleate [jan]
29. Hms3885o07
30. Indacaterol Maleate [mart.]
31. Hy-14299a
32. Indacaterol Maleate [who-dd]
33. Mfcd20526769
34. Indacaterol Maleate [ema Epar]
35. Ccg-269764
36. Indacaterol Maleate [orange Book]
37. Ac-30121
38. As-10152
39. Ultibro Component Indacaterol Maleate
40. I0927
41. Qva149 Component Indacaterol Maleate
42. S3083
43. Qva-149 Component Indacaterol Maleate
44. D09319
45. Indacaterol Maleate Component Of Utibron
46. Q27137018
47. (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4h- Pyrido(3,2-b)-1,4-oxazin-4-yl)methyl Dihydrogen Phosphate
48. (z)-but-2-enedioic Acid;5-[(1r)-2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one
49. 2(1h)-quinolinone, 5-((1r)-2-((5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino)-1-hydroxyethyl )-8-hydroxy-, (2z)-2-butenedioate (1:1)
50. 2(1h)-quinolinone, 5-((1r)-2-((5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino)-1-hydroxyethyl)-8-hydroxy-, (2z)-2-butenedioate (1:1)
51. 435273-74-8
52. 5,6-diethyl-n-[(2r)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]indan-2-aminium (2z)-3-carboxyacrylate
53. 5-((1r)-2-((5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino)-1-hydroxyethyl)-8- Hydroxyquinolin-2(1h)-one Hydrogen (2z)-2-butenedioate (salt)
54. 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1h-quinolin-2-one Maleate
55. 5-{(1r)-2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1h)-one (2z)-but-2-enedioate
Molecular Weight | 508.6 g/mol |
---|---|
Molecular Formula | C28H32N2O7 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 8 |
Exact Mass | 508.22095136 g/mol |
Monoisotopic Mass | 508.22095136 g/mol |
Topological Polar Surface Area | 156 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 708 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Arcapta neohaler |
PubMed Health | Indacaterol (By breathing) |
Drug Classes | Bronchodilator |
Drug Label | ARCAPTA NEOHALER consists of a dry powder formulation of indacaterol maleate for oral inhalation only with the NEOHALERinhaler. The inhalation powder is packaged in clear gelatin capsules.Each clear, hard gelatin capsule contains a dry powder blend... |
Active Ingredient | Indacaterol maleate |
Dosage Form | Powder |
Route | Inhalation |
Strength | eq 75mcg base |
Market Status | Prescription |
Company | Novartis |
2 of 2 | |
---|---|
Drug Name | Arcapta neohaler |
PubMed Health | Indacaterol (By breathing) |
Drug Classes | Bronchodilator |
Drug Label | ARCAPTA NEOHALER consists of a dry powder formulation of indacaterol maleate for oral inhalation only with the NEOHALERinhaler. The inhalation powder is packaged in clear gelatin capsules.Each clear, hard gelatin capsule contains a dry powder blend... |
Active Ingredient | Indacaterol maleate |
Dosage Form | Powder |
Route | Inhalation |
Strength | eq 75mcg base |
Market Status | Prescription |
Company | Novartis |
Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
Oslif Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease
R03AC18
R03AC18
R03AC18
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Arcapta neohaler (TN) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Arcapta neohaler (TN), including repackagers and relabelers. The FDA regulates Arcapta neohaler (TN) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Arcapta neohaler (TN) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Arcapta neohaler (TN) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Arcapta neohaler (TN) supplier is an individual or a company that provides Arcapta neohaler (TN) active pharmaceutical ingredient (API) or Arcapta neohaler (TN) finished formulations upon request. The Arcapta neohaler (TN) suppliers may include Arcapta neohaler (TN) API manufacturers, exporters, distributors and traders.
click here to find a list of Arcapta neohaler (TN) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Arcapta neohaler (TN) DMF (Drug Master File) is a document detailing the whole manufacturing process of Arcapta neohaler (TN) active pharmaceutical ingredient (API) in detail. Different forms of Arcapta neohaler (TN) DMFs exist exist since differing nations have different regulations, such as Arcapta neohaler (TN) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Arcapta neohaler (TN) DMF submitted to regulatory agencies in the US is known as a USDMF. Arcapta neohaler (TN) USDMF includes data on Arcapta neohaler (TN)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Arcapta neohaler (TN) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Arcapta neohaler (TN) suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Arcapta neohaler (TN) Drug Master File in Korea (Arcapta neohaler (TN) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Arcapta neohaler (TN). The MFDS reviews the Arcapta neohaler (TN) KDMF as part of the drug registration process and uses the information provided in the Arcapta neohaler (TN) KDMF to evaluate the safety and efficacy of the drug.
After submitting a Arcapta neohaler (TN) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Arcapta neohaler (TN) API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Arcapta neohaler (TN) suppliers with KDMF on PharmaCompass.
A Arcapta neohaler (TN) written confirmation (Arcapta neohaler (TN) WC) is an official document issued by a regulatory agency to a Arcapta neohaler (TN) manufacturer, verifying that the manufacturing facility of a Arcapta neohaler (TN) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Arcapta neohaler (TN) APIs or Arcapta neohaler (TN) finished pharmaceutical products to another nation, regulatory agencies frequently require a Arcapta neohaler (TN) WC (written confirmation) as part of the regulatory process.
click here to find a list of Arcapta neohaler (TN) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Arcapta neohaler (TN) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Arcapta neohaler (TN) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Arcapta neohaler (TN) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Arcapta neohaler (TN) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Arcapta neohaler (TN) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Arcapta neohaler (TN) suppliers with NDC on PharmaCompass.
Arcapta neohaler (TN) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Arcapta neohaler (TN) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Arcapta neohaler (TN) GMP manufacturer or Arcapta neohaler (TN) GMP API supplier for your needs.
A Arcapta neohaler (TN) CoA (Certificate of Analysis) is a formal document that attests to Arcapta neohaler (TN)'s compliance with Arcapta neohaler (TN) specifications and serves as a tool for batch-level quality control.
Arcapta neohaler (TN) CoA mostly includes findings from lab analyses of a specific batch. For each Arcapta neohaler (TN) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Arcapta neohaler (TN) may be tested according to a variety of international standards, such as European Pharmacopoeia (Arcapta neohaler (TN) EP), Arcapta neohaler (TN) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Arcapta neohaler (TN) USP).
LOOKING FOR A SUPPLIER?